A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Astellas Pharma Inc
Alterome Therapeutics, Inc.
Erasca, Inc.
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Tizona Therapeutics, Inc
Genentech, Inc.
University of Chicago
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Hanmi Pharmaceutical Company Limited
Massachusetts General Hospital
M.D. Anderson Cancer Center
Eli Lilly and Company
Eli Lilly and Company
Merck KGaA, Darmstadt, Germany
EMD Serono